Successive loss of flagellar functionality enables stepwise increases in phagocytic resistance.

(A) FACS analysis and (B) gentamicin protection assay of BMDCs co-incubated with PA14 WT, motAB, motCD, or motABmotCD. (C) FACS analysis of cytochalasin D treated BMDCs co-incubated with GFP-expressing PA14 WT, flgK, motAB, motCD, or motABmotCD. (D) Adherent macrophage assay of cells co-incubated with PA14 WT, motAB, motCD, or motABmotCD bacteria at 4°C, warmed to 37 °C, or treated with gentamicin after warming to 37 °C. (E) Gentamicin protection assay of murine peritoneal macrophages co-incubated as indicated with P. aeruginosa PA14 WT or V. cholerae O395 WT in 70 mM, 18 mM, 9 mM, or 4.5 mM NaCl buffers, or in 15 mM NaCl buffer with 135 mM choline chloride. Recovered CFUs are normalized against recovery in HBSS (138 mM NaCl). N≥5, *p<0.05.